NCT00343954View on ClinicalTrials.gov

PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease

PHASE1UnknownINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

Not specified

Conditions

Sickle Cell Disease

Interventions

DRUG

L-citrulline tablets, 1000 mg

Trial Locations (1)

15213

Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center Health System, Pittsburgh

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Angiogenix

INDUSTRY

NCT00343954 - PK and PD Responses to Oral L-Citrulline in Patients With Sickle Cell Disease | Biotech Hunter | Biotech Hunter